

References

I-133

1. Zeichner S, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. *Breast Cancer (Auckl)*. 2016;10:25-36.
2. Liang X, Wu X, Hu C, et al. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials. *Onco Targets Ther*. 2016;9:4061-4074.
3. Sachdev JC and Jahanzeb M. Use of cytotoxic chemotherapy in metastatic breast cancer: putting taxanes in perspective. *Clin Breast Cancer*. 2016;16(2):73-81.
4. Luu T, Kim K, Blanchard S, et al. Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. *Breast Cancer Res Treat*. 2018;167(2):469-478.
5. Yardley D, Arrowsmith E, Daniel B, et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. *Breast Cancer Res Treat*. 2017;164(3):649-658.
6. Burotto M, Edgerly M, Velarde M, et. al. A phase II multi-center study of bevacizumab in combination with ixabepilone in subjects with advanced renal cell carcinoma. *Oncologist*. 2017;22(8):888.
7. Aghajanian C, Filiaci V, Dizon DS, et. al.. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. *Gynecol Oncol*. 2018;150(2):274-281.
8. McCourt CK, Deng W, Dizon DS, et. al. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2017;144(1):101-106.
9. Ixabepilone In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 10, 2012.
10. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Ixabepilone.
11. Micromedex DrugDex Compendium®. 2023. Ixabepilone (Ixempra).
12. National Comprehensive Cancer Network (NCCN). Ixabepilone. NCCN Drugs and Biologics Compendium®. 2023.
13. Ixempra® (Ixabepilone) for injection, for intravenous infusion only [package insert]. R-Pharm US LLC. Princeton, NJ. Revised 01/2023.